There are 2789 resources available
1226P - Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: ePoster Display
1229P - Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations
Presenter: Linlin Zhang
Session: ePoster Display
1230P - Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany
Presenter: Wolfgang M Brueckl
Session: ePoster Display
1231P - Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
Presenter: James Chih-Hsin Yang
Session: ePoster Display
1232P - Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
Presenter: Hollie Bailey
Session: ePoster Display
1233P - EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation
Presenter: Yuxiang Wang
Session: ePoster Display
1234P - Impact of radiotherapy pattern on the prognosis of stage IV lung adenocarcinomas harboring EGFR mutations
Presenter: Yingyun Zhang
Session: ePoster Display